<DOC>
	<DOCNO>NCT00489658</DOCNO>
	<brief_summary>This case series study follow terminate randomised clinical trial nearby location Uganda , combination eflornithine + nifurtimox show promising efficacy safety . The study 's purpose evaluate efficacy safety combination large group late-stage Human African trypanosomiasis ( sleep sickness ) patient .</brief_summary>
	<brief_title>Eflornithine + Nifurtimox Late-Stage Human African Trypanosomiasis ( HAT ) West Nile , Uganda</brief_title>
	<detailed_description />
	<mesh_term>Trypanosomiasis , African</mesh_term>
	<mesh_term>Trypanosomiasis</mesh_term>
	<mesh_term>Eflornithine</mesh_term>
	<mesh_term>Nifurtimox</mesh_term>
	<criteria>Stage 2 infection Trypanosoma brucei gambiense diagnose within previous 14 day , define either follow : ( ) Presence trypanosomes blood lymph node fluid WBC count CSF &gt; 5 / mm3 , ( ii ) Presence trypanosomes CSF CSF WBC count Residence study area Written inform consent ( obtain parent/guardian child 18 year patient impaired cognition ) Pregnancy clinical history suggestive thereof Weight &lt; 10 Kg History HAT treatment within previous 24 month Inability undergo hospitalisation attend followup visit 24 month follow discharge Severe anemia ( Hb &lt; 5g/dl ) Active tuberculosis ( sputum positive ) HIV positive ( patient test result know ) Severe renal hepatic failure Bacterial cryptococcal meningitis Other severe underlie disease upon admission Refugee status</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2007</verification_date>
	<keyword>Human African trypanosomiasis</keyword>
	<keyword>sleep sickness</keyword>
	<keyword>Trypanosoma brucei gambiense</keyword>
	<keyword>combination</keyword>
	<keyword>eflornithine</keyword>
	<keyword>nifurtimox</keyword>
	<keyword>Human African trypanosomiasis ( sleep sickness ) due Trypanosoma brucei gambiense late stage ( stage 2 meningo-encephalitic )</keyword>
</DOC>